Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

Independent practices face challenges from consolidation and policy shifts, with hybrid models offering autonomy while sharing financial risk. Value-based care in oncology prioritizes science, ...

CAGR is driven by advancements in epigenetics research, methylation analysis technologies, and the rising need for ...

A landmark study, titled “How error correction affects polymerase chain reaction deduplication: A survey based on unique molecular identifier datasets of short reads” recently published in ...

Next-generation sequencing (NGS) has moved away from expensive runs and complicated workflows into a new era where benchtop instruments prioritize sustainability, accessibility, accuracy, and speed.

Automated library preparation is critical for reducing errors, increasing repeatability, and reducing hands-on time, allowing researchers to generate sequence data from DNA more quickly. The CyBio ...

Researchers at University of Tsukuba have decoded the nuclear genome of Amorphochlora amoebiformis, a unicellular marine alga ...